Please Note
We brought you to this page based on your search query. If this isn't what you are looking for, you can continue to Search Results for ""
The maximum number of items you can export is 3,000. Please reduce your list by using the filtering tool to the left.
Close
Chystáte se opustit lokální stránky Czech Proto budete přesměrování na celosvětové stránky, které jsou dostupné?
Nezobrazujte znovu tuto zprávu
Ano
Ne

Vyhledávali jste podle

Hledali jste

Relevantní informace

Důležité kontakty

Připravované akce

Příbuzné produkty

Farmaceutika, všeobecně a speciální - Irsko

Nejdůležitější body

Výzkum a studie
Organizace
Upřesněte, prosím, svou studii podle segmentu trhu, aby bylo možno získat odpovídající ratingy a monitorované údaje.
  DatumTyp dokumentu Název Emitent/entita
15 Apr 2024 Issuer Profile Jazz Pharmaceuticals plc: Key facts and statistics - 2023 Jazz Pharmaceuticals plc
28 Feb 2024 Rating Action Moody's affirms Alkermes' Ba3 CFR, outlook stable Alkermes plc
Alkermes, Inc.
31 Jan 2024 Credit Opinion Jazz Pharmaceuticals plc: Update following upgrade of CFR to Ba2 Jazz Pharmaceuticals plc
25 Jan 2024 Rating Action Moody's upgrades Jazz Pharma's CFR to Ba2; stable outlook Jazz Financing ...
Jazz Financing ...
Jazz Pharmaceut...
Jazz Pharmaceut...
Jazz Securities...
11 Dec 2023 Announcement of Periodic Review Moody's announces completion of a periodic review for a group of Conglomerates, Investment Holding, Pharmaceuticals and Other issuers in Asia Pacific Astellas Pharma...
Baxalta Incorpo...
Beijing Capital...
Beijing Capital...
China Jianyin I...
CK Hutchison Ca...
CK Hutchison Eu...
CK Hutchison Eu...
CK Hutchison Fi...
CK Hutchison Fi...
...
27 Jul 2023 Announcement of Periodic Review Moody's announces completion of a periodic review for a group of Pharmaceutical issuers AbbVie Inc.
Alkermes, Inc.
Alvogen Pharma ...
Amgen Inc.
Amneal Pharmace...
ANI Pharmaceuti...
Azurity Pharmac...
Bausch + Lomb C...
Bausch Health A...
Bausch Health C...
...
20 Jul 2023 Rating Action Moody's downgrades Mallinckrodt's CFR to Ca following missed interest payments, outlook remains negative Mallinckrodt In...
Mallinckrodt pl...
26 Jun 2023 Rating Action Moody's upgrades Takeda's rating to Baa1, changes outlook to stable
 The document has been translated in other languages

Baxalta Incorpo...
Shire Acq Inv I...
Takeda Pharmace...
25 May 2023 Rating Action Moody's downgrades Mallinckrodt's CFR to Caa1; outlook negative Mallinckrodt In...
Mallinckrodt pl...
16 May 2023 Announcement Moody's: Amgen's and Horizon Therapeutics' ratings unaffected by FTC recent filing to block the acquisition Amgen Inc.
Horizon Therape...
Horizon Therape...
Complete Your Profile
Please complete your profile before submitting your comments.
We're Sorry